In an in vitro pharmacodynamic model, a twice-daily cefdinir dosing regimen was more effective than a once-daily regimen against common bacterial respiratory pathogens in producing 3-log10 killing and preventing the occurrence of regrowth at 24 h. Twice-daily administration is likely the more appropriate cefdinir dosing strategy for the treatment of community-acquired pneumonia.
|Original language||English (US)|
|Number of pages||3|
|Journal||Antimicrobial agents and chemotherapy|
|State||Published - 2001|